肺鳞30月，父亲永远地走了

6 |0 ?2 l7 J4 d) ~" |; c
, L0 k" w! {. c9 a6 h4 ^1 p; O4.15 复查
医生认为CT才做一个月，结果稳定，这次查个血就够了，我认同，上次就CA125增长比较多，这次开单查了CEA、CA125、CA153、CA199，NSE。去年9月之前没记录，尚未找到规律，再来几次可能就知道哪个敏感了。
& J# q* Z" ^, V% F如果2992还有效，是否改成吃8停5？目前状态很好，乳铁蛋白有奇效？

4.17 昨天抽了血，今天出报告：
5 B" M3 \4 T; q! a3 l: A, pCEA 1.76
& K8 I3 ~" E# k4 NCA125 162.6 继续升高，估计2992耐药或部分耐药了
! y' ?/ Y* ?7 {) g, A% O# M/ SCA199 8.48
/ Z: S* v, f9 }% _/ V3 b! k% Q& E7 Z1 {CA153 17.82
NSE 14.95
& u' V% [8 c+ y8 q) M  T

CT上个月做稳定，因此这次未做，CA125继续上升，纠结要不要化疗。医生提议目前生活质量很好，以CT为准，暂不管指标上升。
8 I# N& v) {+ E( q纠结ing

: h; X- _4 t. O! k现在考虑的方案：
1、试试易(平安老师认为肺癌不试试易可惜）
5 _6 N( m7 R. x! S2、2992+半量xl184
# |1 t, b! F; W, E. c6 }( u3、2992加量
凡德有试过，无效
) Z! }% E! n! `) z4 t8 {0 M4 t+ M

爱老虎油！ 2013/4/17 星期三 18:56:31
, [% T" k1 c& \5 s- H1 Q易用过吗？没用过试试易吧，肺，不用易太可惜了
滴水(luxd)  20:20:13
平安姐，我父亲是鳞、吸烟，是不是也试试
; u$ u# L; c: ^2 X滴水(luxd)  20:34:25
8 W2 }' S) \7 I之前就是考虑鳞+男性+吸烟，直接上的特。现在考虑：
1 C9 G6 \3 B, o+ K8 c1、试试易
+ p( N$ c) F% M* @( ?3 m2、2992+半量xl184
. n* y" W# s- n/ {' a# x( H3、2992加量
8 t+ Z0 y4 q* A+ q' m凡德有试过，无效
! `6 w4 z; B1 l$ d4 P爱老虎油！  21:31:42
/ H' ]4 \& ], a( M& y8 D! E" R如果病情紧急就上2，不紧急就试试易

  K1 @( l; a' ^/ a7 L2 q
+ t4 m. A4 R0 j6 k; @考虑方案4：替吉奥

S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.

& H" g, t: V) A替的疾病控制率，腺比非腺高很多：57.9%vs20%

S-1联合铂类，效果与病理类型无关（即鳞和腺相当），这与培美不同，可能是作用TS的方式不同。
9 y% e6 Q3 r4 P4 X" i- y2 Fhttp://ar.iiarjournals.org/content/30/7/2985.full.pdf
8 O, ?8 H& {! ~0 k单药却与病理类型有关？

综合平安老师、老马建议和自己判断，决定采用方案四，口服替吉奥。原因：
) W! @+ G4 ~+ U/ a0 N9 {1、特、2992均已耐药，易有效的可能性很低；
2、2992趋于耐药，如果没有有效手段，反正都要化疗了，口服替是比较轻松的化疗方案；
3、如果不准备把2992用绝，联用方案也先不考虑：
--2992+184，平安老师认为在危急的时候用；
1 Y% z& j3 [9 S0 U2 s8 q) y! v# E--2992+替http://www.ncbi.nlm.nih.gov/pubmed/20530710，2992已经耐药，就先不考虑联用了；
- W$ J7 w2 t$ M! }5、如果替有效，那怕只是稳定，也为切换回特创造条件，如果无效，就去多西他赛化疗。
还有什么要考虑的？每次情况变化，做决定都是犹豫不决。

4.22 开始替吉奥，60mg bid

关注！

论坛里有好几家在用替，关注中。